Edition:
United States

Vectura Group PLC (VEC.L)

VEC.L on London Stock Exchange

80.80GBp
7:51am EDT
Change (% chg)

-0.85 (-1.04%)
Prev Close
81.65
Open
81.00
Day's High
82.10
Day's Low
80.55
Volume
1,185,532
Avg. Vol
5,074,442
52-wk High
127.22
52-wk Low
68.00

Latest Key Developments (Source: Significant Developments)

Vectura Says To Date Revenues Are In Line With Its Expectations For Full Year
Thursday, 17 May 2018 02:01am EDT 

May 17 (Reuters) - Vectura Group PLC ::BASED ON OVERALL TRADING PERFORMANCE TO DATE IN 2018 BOARD CONFIRMS THAT GROUP'S REVENUES ARE IN LINE WITH ITS EXPECTATIONS FOR FULL YEAR.  Full Article

Vectura Group Posts FY Reported Revenue Of 148.0 Mln Pounds‍​
Wednesday, 21 Mar 2018 03:02am EDT 

March 21 (Reuters) - Vectura Group Plc ::FULL YEAR REPORTED REVENUE OF £148.0 MILLION, IN LINE WITH BOARD EXPECTATIONS (REPORTED 9M 2016: £126.5 MILLION)‍​.2016 FULL-YEAR PROFORMA REVENUE WAS £183.6 MILLION‍​.MAINTAINS 2018 REVENUE GROWTH EXPECTATIONS AND REITERATES PREVIOUSLY-REDUCED RESEARCH AND DEVELOPMENT INVESTMENT GUIDANCE RANGE OF £55 MILLION TO £65 MILLION FOR YEAR ‍​.2017 UNDERLYING REVENUE WAS £131.4 MILLION; +4.0% DRIVEN BY THE GROUP'S KEY-INHALED PRODUCTS.ENDED THE YEAR WITH A CLOSING CASH BALANCE OF £103.7 MILLION (31 DECEMBER 2016: £92.5 MILLION).FY ADJUSTED EBITDA WAS AHEAD OF EXPECTATIONS AT £25.8 MILLION PROFIT (REPORTED 9M 2016: £34.1 MILLION PROFIT).NOTWITHSTANDING DISAPPOINTING DELAYS CO SEEN FOR VR315 (US) GENERIC ADVAIR PROGRAMME, CONTINUE TO SEE SUBSTANTIAL VALUE IN DEVELOPMENT OF COMPLEX INHALED GENERICS‍​.LOOK FORWARD TO A SERIES OF SIGNIFICANT NEWS FLOW CATALYSTS DURING 2018.  Full Article

Vectura Group Anticipates FY 2017 Revenue In Line With Board's Expectations
Thursday, 4 Jan 2018 02:00am EST 

Jan 4 (Reuters) - Vectura Group Plc ::FULL YEAR 2017 REVENUE ANTICIPATED TO BE IN LINE WITH BOARD'S EXPECTATIONS.FLUTIFORM PRODUCT SUPPLY REVENUE IN H2 2017 IS IN LINE WITH GUIDANCE PROVIDED.FLUTIFORMQ3 1 IN-MARKET NET SALES WERE EUR 47.8 MILLION 2 , UP 12% AT CONSTANT EXCHANGE RATES.ULTIBRO Q3 1 NET SALES OF $101 MILLION, WITH 18% GROWTH IN EUROPE YEAR-ON-YEAR.ROYALTIES FROM GSK ELLIPTA® PRODUCTS ACHIEVED £9 MILLION ANNUAL CAP IN Q3.WERE CURRENT EXCHANGE RATES TO CONTINUE THROUGH 2018, STERLING REPORTED REVENUES WOULD BE REDUCED BY APPROXIMATELY £5.0 MILLION.RESEARCH AND DEVELOPMENT COSTS IN 2018 ARE EXPECTED TO REDUCE TO £55 MILLION - £65 MILLION (PREVIOUS 2018 GUIDANCE: £65 MILLION - £75 MILLION).  Full Article

Vectura Group posts HY revenue of 78.8 million pounds
Wednesday, 6 Sep 2017 02:03am EDT 

Sept 6 (Reuters) - Vectura Group Plc :H1 PRETAX LOSS 44.5 MILLION STG.HY REVENUE 78.8 MILLION POUNDS VERSUS 73.9 MILLION POUNDS A YEAR AGO.HY RECURRING REVENUE PERCENT OF TOTAL REVENUE 90.1 PERCENT VERSUS 76.2 PERCENT A YEAR AGO.HY RECURRING REVENUE 71 MILLION POUNDS VERSUS 56.3 MILLION POUNDS A YEAR AGO.DETAILED REVIEW OF PRIORITIES FOR RESEARCH AND DEVELOPMENT PROGRAMMES IN 2017 UNDERTAKEN AND EXPENDITURE FOR FY IS NOW EXPECTED TO BE LOWER, AT £60 MILLION - £70 MILLION."SINCE CRL, VECTURA SUPPORTED HIKMA IN CONSTRUCTIVE DIALOGUE WITH FDA AND A NUMBER OF QUESTIONS RAISED HAVE NOW BEEN CLARIFIED AND RESOLVED"."EXPECTS TO BE ABLE TO CONFIRM REGULATORY TIMETABLE BEFORE END OF 2017".IN LINE WITH BOARD'S EXPECTATIONS, REMAINS ON TRACK TO DELIVER ORIGINAL £10 MILLION TARGET ANNUAL COST SYNERGIES BY 2018 WITH MAJORITY REALISED IN 2017.FURTHER ANNUAL NON-HEADCOUNT COST SYNERGY OPPORTUNITIES OF £1 MILLION - £2 MILLION FROM 2018 HAVE BEEN IDENTIFIED."THERE IS PRODUCTIVE DIALOGUE AND PROGRESS BEING MADE WITH FDA FOLLOWING RECEIPT OF MAJOR CRL FOR VR315 ADVAIR GENERIC IN US, CONCLUDING NUMBER OF OPEN QUESTIONS" - CEO.MAINTAINS PREVIOUS GUIDANCE OF £65 MILLION - £75 MILLION ANNUAL RESEARCH AND DEVELOPMENT EXPENDITURE FOR 2018.  Full Article

Vectura announces ANDA filing for US generic version of Advair Diskus
Thursday, 17 Aug 2017 02:06am EDT 

Aug 17 (Reuters) - VECTURA GROUP PLC ::CONFIRMS STATEMENT MADE BY PARTNER HIKMA IN RESPECT OF ANDA FILING FOR A US GENERIC VERSION OF ADVAIR DISKUS.  Full Article

Vectura says global development agreement with Dynavax
Wednesday, 16 Aug 2017 02:00am EDT 

Aug 16 (Reuters) - VECTURA GROUP PLC ::GLOBAL DEVELOPMENT AGREEMENT WITH DYNAVAX.VECTURA'S AKITA SMART NEBULISER TO BE USED BY DYNAVAX TO DELIVER DV281.VECTURA ELIGIBLE TO RECEIVE MODEST MILESTONES, DEVELOPMENT SERVICES REVENUES.DOES NOT EXPECT MATERIAL IMPACT ON R&D EXPENDITURE WHICH REMAINS WITHIN PREVIOUS ANNUAL GUIDANCE RANGE OF £65-75M FOR 2017 AND 2018.  Full Article

Vectura inks new U.S. deals for generic asthma therapy​
Wednesday, 28 Jun 2017 12:14pm EDT 

June 28 (Reuters) - Vectura Group Plc ::‍New development and licence agreement for a U.S. inhaled generic​.Signed exclusive development and licence agreement with Sandoz for development of a generic of an existing major inhaled combination therapy for asthma and COPD in U.S.​.‍responsible for development of formulation and manufacture of clinical batches for use in pilot clinical studies​.‍sandoz is responsible for clinical development, manufacture and commercialisation of vr2081​.Will receive an initial payment of $5 million from Sandoz.Eligible to receive up to further $5 million upon achievement of pre- determined development milestones​.‍Also eligible to receive a double digit percentage royalty on net sales in line with our other generic development programmes​.Total research and development cost borne by vectura is expected to be below $20 million up to regulatory filing and subsequent launch, which is seen in early to mid-2020's​.‍Expected that $5 million initial milestone will be recognised in revenues across 2017 and 2018​.‍Overall research and development guidance range of £65 million - £75 million for each of 2017 and 2018 remains unchanged​.  Full Article

Vectura says US licensee of group's partner Novartis AG launched Utibron Neohaler in US
Monday, 3 Apr 2017 11:56am EDT 

Vectura Group Plc : Sunovion Pharmaceuticals, US licensee of group's partner Novartis AG launched Utibron Neohaler in US .Sunovion confirmed it expect to launch Seebri in US during next twelve months.  Full Article

Vectura posts 9-month loss before taxation of 40.1 million stg
Tuesday, 21 Mar 2017 03:28am EDT 

Vectura Group Plc : Nine-Month pretax loss 40.1 million stg versus loss of 1.9 million stg for 12 months ended March 31, 2016 . 9-month revenue 126.5 million stg . 9-month basic loss per share 5.3 pence . Sees 2018 capex of GBP 10 million - GBP 15 million . Targets annual synergy savings of at least £10 million by 2018 .Sees 2017 capex of GBP 15 million - GBP 20 million.  Full Article

Vectura signs deal with Mundipharma on respiratory treatments
Friday, 23 Dec 2016 02:16am EST 

Vectura Group Plc : Global development programme with Mundipharma for PMDI inhaled triple therapy (VR2076) for asthma and COPD . Exercise of this option triggers a payment to vectura of eur 1.5 million . If Mundipharma decides to develop programme in COPD, Vectura eligible for further potential milestones of up to eur 20.0 million . In December 2015, companies entered into a feasibility and option agreement .Further total potential milestone payments up to eur 46.5 million are receivable linked to milestones, future net sales of product.  Full Article